Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of NLC nanoparticles containing hydroquinone, tretinoin, and fluocinolone in the treatment of melasma
IRCT20161207031288N13Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of fluocinolone acetonide + hydroquinone + tretinoin in melasma, sponsored by Tehran University of Medical Sciences. Started Jul 2022; status: completed.
02
Drugs
fluocinolone acetonide + hydroquinone + tretinoin
03
Conditions
melasma
Beyond the preview
Go deeper on IRCT20161207031288N13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20161207031288N13.